SharkNinja Inc. Ordinary Shares vs TG Therapeutics Inc — how do they compare? SharkNinja Inc. Ordinary Shares trades at $184.98 (market cap $26.04B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: SharkNinja Inc. Ordinary Shares is far larger — about 3.2× TG Therapeutics Inc's market cap, and SharkNinja Inc. Ordinary Shares is more actively traded (994,345 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold SharkNinja Inc. Ordinary Shares for 1 Days and TG Therapeutics Inc for 16 Days on average.
| SN | TGTX | |
|---|---|---|
Market Cap | $26.04B | $8.16B |
Volume | 994,345 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $192.86 | $59.06 |
52-Week Low | $84.57 | $26.94 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $26.18B | $8.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →